Ticker

Analyst Price Targets — ALG

Page 1 • Showing up to 10
DateAnalystFirmTargetPrice @ PostSourceHeadline
July 1, 2026 12:37 pmMichael ShilskyD.A. Davidson$188.00$163.71StreetInsider DA Davidson Reiterates Neutral Rating on Alamo Group (ALG)
May 11, 2026 1:02 pmIndustrial Alliance Securities$188.00$155.18TheFly Alamo Group price target lowered to $188 from $190 at DA Davidson
March 9, 2026 12:40 pmMichael ShilskyD.A. Davidson$190.00$160.49StreetInsider Alamo Group (ALG) Reiterated at Neutral by DA Davidson After Q4 Earnings
March 3, 2025 2:24 pmIndustrial Alliance Securities$217.00$176.02TheFly Alamo Group price target lowered to $217 from $219 at DA Davidson
February 28, 2025 9:53 amRobert W. Baird$177.00$174.98TheFly Alamo Group downgraded to Neutral from Outperform at Baird
August 5, 2024 7:57 amMichael ShilskyD.A. Davidson$209.00$169.41StreetInsider Alamo Group (ALG) PT Lowered to $209 at DA Davidson
May 7, 2024 9:20 amMichael ShliskyD.A. Davidson$225.00$193.28TheFly Alamo Group price target lowered to $225 from $235 at DA Davidson
February 27, 2023 8:01 amDan DolevMizuho Securities$241.00$178.25Benzinga MannKind To Rally Around 30%? Here Are 10 Other Analyst Forecasts For Monday
October 19, 2022 2:12 pmTim MooreEF Hutton$195.00$143.95Benzinga Alamo Warrants Higher Valuation, Says Analyst

Latest News for ALG

Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China

SOUTH SAN FRANCISCO, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that dosing has been initiated in the Phase 1 study of ALG-170675, an investigational next-generation antisense oligonucleotide (ASO) being evaluated for…

GlobeNewsWire • Aug 12, 2026
Alamo Group Q2 Earnings Call Highlights

Alamo Group NYSE: ALG reported second-quarter 2026 net sales of $415.7 million, up 7.6% from a year earlier, as acquisitions and modest organic growth supported results. Organic net sales rose 1.3%, while adjusted diluted earnings per share increased 7.2% to $2.82.

MarketBeat • Aug 4, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for ALG.

House Trades Disclosures

NameTransaction DateTypeAssetAmountLink

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top